Adagio Medical Raises $19M in Private Placement

An update from Adagio Medical Holdings ( (ADGM) ) is now available.

On October 14, 2025, Adagio Medical Holdings entered into a Securities Purchase Agreement with accredited investors to raise approximately $19 million upfront through a private placement of common stock and warrants, with potential additional proceeds of up to $31 million upon full exercise of the warrants. The funds will be used for working capital and advancing clinical and product development activities, potentially strengthening Adagio’s market position in cardiac arrhythmia treatment technologies.

The most recent analyst rating on (ADGM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Spark’s Take on ADGM Stock

According to Spark, TipRanks’ AI Analyst, ADGM is a Neutral.

Adagio Medical Holdings faces significant financial challenges, with consistent losses and negative cash flows being the most impactful factors. While technical indicators suggest some positive momentum, the company’s negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on ADGM stock, click here.

More about Adagio Medical Holdings

Adagio Medical Holdings, Inc. is a medical device company specializing in the development and commercialization of products for treating cardiac arrhythmias using its proprietary Ultra-Low Temperature Cryoablation (ULTC) technology. The company is focused on treating ventricular tachycardia with its vCLAS Cryoablation System, which has received CE Mark approval and is under evaluation in a pivotal study in the U.S.

Average Trading Volume: 298,363

Technical Sentiment Signal: Hold

Current Market Cap: $29.38M

For a thorough assessment of ADGM stock, go to TipRanks’ Stock Analysis page.